Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126605051 | 12660505 | 1 | I | 20160811 | 20160817 | 20160817 | EXP | DK-MYLANLABS-2016M1034372 | MYLAN | ANDERSEN NB, BOYSEN AK, ROSSEN PB, LUCKE AO, SAFWAT AA. BILATERAL AVASCULAR NECROSIS OF THE FEMORAL HEAD FOLLOWING TREATMENT OF EWING^S SARCOMA. ACTA-ONCOL 2016;55(6):792-795. | 0.00 | Y | 0.00000 | 20160817 | OT | DK | DK |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126605051 | 12660505 | 1 | PS | DOXORUBICIN | DOXORUBICIN | 1 | Unknown | 20 MG/M2 ON DAYS 1-3 FOR SIX CYCLES | U | U | 200170 | ||||||||
| 126605051 | 12660505 | 2 | SS | ETOPOSIDE. | ETOPOSIDE | 1 | Unknown | 150 MG/M2 ON DAYS 1-3 FOR SIX CYCLES | U | U | 0 | ||||||||
| 126605051 | 12660505 | 3 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Unknown | 3 MG/M2 ON DAYS 1-3 FOR SIX CYCLES | U | U | 0 | ||||||||
| 126605051 | 12660505 | 4 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Other | TWO CYCLES BY CONTINUOUS INFUSION BY PUMP | U | U | 0 | ||||||||
| 126605051 | 12660505 | 5 | SS | IFOSFAMIDE. | IFOSFAMIDE | 1 | Unknown | 3 MG/M2 ON DAYS 1-2 FOR SIX CYCLES | U | U | 0 | ||||||||
| 126605051 | 12660505 | 6 | SS | IRINOTECAN | IRINOTECAN | 1 | Unknown | 10 MG/M2 ON DAYS 1-5 | U | U | 0 | ||||||||
| 126605051 | 12660505 | 7 | SS | PREDNISOLONE. | PREDNISOLONE | 1 | Unknown | U | U | 0 | |||||||||
| 126605051 | 12660505 | 8 | SS | TEMOZOLOMIDE. | TEMOZOLOMIDE | 1 | Unknown | 100 MG/M2 ON DAYS 1-5 | U | U | 0 | ||||||||
| 126605051 | 12660505 | 9 | SS | DACTINOMYCIN | DACTINOMYCIN | 1 | Unknown | 0.75 MG/M2 ON DAY 1-2 FOR SIX CYCLES | U | U | 0 | ||||||||
| 126605051 | 12660505 | 10 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | 1.5 MG/M2 ON DAY 1 FOR SIX CYCLES | U | U | 0 | ||||||||
| 126605051 | 12660505 | 11 | SS | VINCRISTINE | VINCRISTINE | 1 | Unknown | 1.5 MG/M2 ON DAY 1 FOR SIX CYCLES | U | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126605051 | 12660505 | 7 | Antiemetic supportive care |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126605051 | 12660505 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126605051 | 12660505 | Osteonecrosis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |